Alex Azar served as the 24th Secretary of the U.S. Department of Health and Human Services from 2018 to 2021, where he made significant strides in healthcare policy and public health. His tenure was marked by a strong commitment to improving the health of Americans, focusing on initiatives that aimed to enhance access to healthcare and reduce prescription drug prices. Azar’s leadership during the COVID-19 pandemic was particularly noteworthy, as he played a crucial role in coordinating the federal response and ensuring the availability of vaccines and treatments.
Prior to his role as Secretary, Azar held several key positions within the U.S. Department of Health and Human Services. He served as the General Counsel from 2001 to 2005, where he provided legal guidance on a range of health policy issues. Following this, he was appointed Deputy Secretary, where he oversaw the implementation of various health programs and policies, demonstrating his ability to navigate complex regulatory environments and drive impactful change.
Azar’s experience in the private sector as President of the U.S. division of Eli Lilly and Company from 2012 to 2017 further enriched his perspective on healthcare. His leadership at Eli Lilly involved strategic initiatives that advanced the company’s mission in the pharmaceutical industry, showcasing his expertise in both public and private healthcare sectors.
Currently, Azar is a senior executive in residence at the Miami Herbert Business School, where he continues to influence the next generation of leaders in healthcare. His extensive background in law, business, and public service positions him as a prominent figure in the ongoing dialogue about health policy and reform.